Biomedtracker and Datamonitor Healthcare present the post-report for the 66th Annual Meeting of the American
Society of Hematology (ASH) held in Orlando, Florida from December 6-9, 2024. Conference highlights include:

• Updated data from the Phase I/IIa Venetoclax/Azacitidine combination therapy study showcasing the potential of SELLAS Life Sciences’ SLS-009 in acute myeloid leukemia.
• Promising Phase II data from the iMMagine-1 study of anito-cel in multiple myeloma.
• Top-line results from the Phase III ACCESS-1 study and ACCESS extension study evaluating poze-cemdi in patients with paroxysmal nocturnal hemoglobinuria (PNH) who are naïve to, or have not recently received, complement inhibitor therapy.

This post-meeting report features commentary from our analysts on specific presentations. It also includes a
compilation of all data events added in conjunction with the meeting.